Fig 1.
Flow diagram of study protocol.
Table 1.
Patient characteristics.
Fig 2.
Kaplan-Meier curve of overall survival and progression-free survival.
Fig 3.
Swimmer’s plot of time to progression, time to toxicity causing early discontinuation of study drug, and time to death (overall survival). Three of three patients who progressed on CPI-613 and were subsequently started on topotecan then demonstrated treatment response with survival for 547, 223, and 153 days (dark blue rows).
Table 2.
Summary of toxicities with related or probable attribution.
Fig 4.
In vitro assessment of the combination of CPI-613 with topotecan.
DMS-114 and NCI-H69 SCLC cell lines were exposed to the indicated drug for 72 hours and then cell viability was assessed. Combinatorial indices were calculated for the indicated drug combinations. CI = Combinatorial Index, CPI = CPI-613, Tec = Topotecan.